Can acetabula midge used to treat after symptoms of acute mountain sic

Can acetabula midge used to treat after symptoms of acute mountain sickness appears

Reading File

Finding Sources

Searching PubMed

acetazolamide "acute mountain sickness" treatment

Reading File

I now have comprehensive information to answer this question fully.

Acetazolamide for Acute Mountain Sickness (AMS) - After Symptoms Appear

I believe you're asking about acetazolamide (the query appears to be a voice-to-text distortion of the drug name). Yes - acetazolamide can be used for treatment after AMS symptoms appear, not just for prevention.

What is Acetazolamide?

Acetazolamide is a carbonic anhydrase inhibitor that induces a mild metabolic acidosis, which indirectly stimulates respiration via peripheral and medullary chemoreceptors. This increased ventilation helps counteract the hypoventilation that underlies altitude illness. Its FDA-approved indications explicitly include AMS for both prophylaxis AND adjunctive treatment.

Fishman's Pulmonary Diseases and Disorders, p. 675

For Treatment (After Symptoms Appear)

Once AMS symptoms have developed, acetazolamide is used at a higher dose than prevention:

Role	Dose	Route
Treatment of AMS	250 mg twice daily	Oral
Prevention (prophylaxis)	62.5-125 mg twice daily	Oral
Pediatric treatment	2.5 mg/kg every 12 hr	Oral

For less severe symptomatic AMS, acetazolamide (250 mg twice daily) or dexamethasone (4 mg every 6 hours) are both effective options.

Goldman-Cecil Medicine, p. 1465

Important Hierarchy: Symptom Severity Matters

The treatment approach depends on how severe the symptoms are:

Life-threatening symptoms (high-altitude pulmonary edema / HACE):
- Immediate descent is the best treatment
- Supplemental oxygen
- Portable hyperbaric chamber if needed
- Acetazolamide is adjunctive here, not first-line
Moderate/less severe AMS symptoms:
- Acetazolamide 250 mg twice daily - appropriate first-line treatment
- OR dexamethasone 4 mg every 6 hours
Mild AMS (e.g., headache only):
- NSAIDs (ibuprofen, aspirin), acetaminophen are sufficient
- Acetazolamide is still appropriate but may be more than necessary

Goldman-Cecil Medicine, pp. 1463-1465

Why It Works (Mechanism)

Acetazolamide inhibits carbonic anhydrase, causing:

Bicarbonate wasting in the kidney → mild metabolic acidosis
The acidosis directly stimulates chemoreceptors → increases respiratory rate and depth
Better ventilation → improved oxygenation at altitude
Also may increase cerebral blood flow independently

Side Effects to Know

Peripheral tingling/numbness (paresthesias - very common)
Polyuria (diuresis)
Drowsiness
Hypokalemia
GI upset
Contraindicated in sulfa allergy (sulfonamide derivative)

Summary

Yes, acetazolamide can and should be used after AMS symptoms appear, at 250 mg orally twice daily. It is FDA-approved for both prevention and treatment of AMS. However, if symptoms are severe (pulmonary edema, cerebral edema, altered consciousness), immediate descent takes priority over any medication.

Recent network meta-analyses (PMID 34758521, PMID 40383249) continue to support acetazolamide's effectiveness for altitude sickness management, consistent with longstanding guideline recommendations.

Symptoms and how to detect acute mountain sickness

Finding Sources

Reading File

Excellent - I now have everything needed for a thorough, well-sourced answer.

Acute Mountain Sickness (AMS): Symptoms and Detection

What is AMS?

AMS is the most common form of acute altitude illness, affecting 22-50% of travelers to altitudes between 1,850-4,240 m (6,000-14,000 ft). At popular trekking routes like Mount Kilimanjaro, rates as high as 70% have been reported with rapid ascent. It results from hypoxia triggering a series of pathophysiologic responses - primarily cerebral vasodilation and early cerebral edema.

Murray & Nadel's Respiratory Medicine, p. 3630
Guyton & Hall Medical Physiology, p. 3785

Symptoms

Cardinal (Required) Symptom

Headache is the hallmark symptom and is required for diagnosis under the Lake Louise Criteria. It is typically:

Bitemporal (both sides of the forehead/temples)
Throbbing in character
Worse at night, on awakening, or when suddenly standing upright

Associated Symptoms (at least 1 required alongside headache)

Symptom	Description
Gastrointestinal	Anorexia (loss of appetite), nausea, vomiting
Fatigue / weakness	Lassitude, feeling drained, inability to exert
Dizziness / lightheadedness	May range from mild to near-fainting
Sleep disturbance	Frequent waking, periodic (Cheyne-Stokes) breathing at night

Note: Sleep disturbance was previously a formal criterion but was removed from the revised Lake Louise Score after studies showed it was not closely correlated with true AMS.

Rosen's Emergency Medicine, p. 419
Murray & Nadel's, p. 3632-3633

Physical Signs (generally few)

AMS is largely a clinical/subjective diagnosis - there are no pathognomonic physical findings. However, some patients may show:

Mildly elevated body temperature
Crackles on lung auscultation (early)
Peripheral edema
Lower oxygen saturation (SpO2) compared to healthy individuals at the same altitude - though AMS can still occur with normal SpO2

Time Course

Timepoint	What Happens
Immediately on arrival	No symptoms yet
6-10 hours after ascent	Symptoms begin to appear
Within 12 hours	~65% of those who develop AMS will have symptoms
12-36 hours	Remaining ~34% develop symptoms
24-48 hours	Symptoms at maximum severity
3-4 days	Most become symptom-free as the body acclimatizes
After 36 hours	Onset after this point is uncommon - consider alternative diagnoses

Murray & Nadel's, p. 3640-3644

How to Detect AMS: The Lake Louise Score (LLS)

The standard clinical tool is the Lake Louise Acute Mountain Sickness Self-Questionnaire - a scored checklist the patient fills out themselves.

Symptom	Score
Headache: None=0 / Mild=1 / Moderate=2 / Severe/incapacitating=3	0-3
GI symptoms: None=0 / Poor appetite or nausea=1 / Moderate nausea or vomiting=2 / Severe nausea+vomiting=3	0-3
Fatigue/weakness: None=0 / Mild=1 / Moderate=2 / Severe=3	0-3
Dizziness: None=0 / Mild=1 / Moderate=2 / Severely lightheaded/fainting=3	0-3
Sleep: Slept well=0 / Not as well as usual=1 / Woke many times=2 / Could not sleep at all=3	0-3

Diagnosis requires: headache + at least 1 other symptom above

Total Score	Severity
2-4	Mild AMS
5-9	Moderate AMS
10-15	Severe AMS

Tintinalli's Emergency Medicine, Table 216-2

Warning Signs: When AMS is Progressing to Something Worse

Two dangerous complications must be recognized immediately:

1. High-Altitude Cerebral Edema (HACE)

Ataxia (loss of coordination - cannot walk a straight line)
Altered mental status (confusion, disorientation, drowsiness)
These mandate immediate descent - do NOT wait

2. High-Altitude Pulmonary Edema (HAPE)

Dyspnea at rest (shortness of breath even when not moving)
Dry cough progressing to productive/frothy cough
Note: Dyspnea on exertion alone is normal at altitude and does not indicate HAPE
Rosen's Emergency Medicine, p. 437-439

Differential Diagnoses to Rule Out

Because AMS symptoms are nonspecific, the following must be considered:

Dehydration
Hypothermia
Hyponatremia
Exhaustion
Acute carbon monoxide poisoning (common in poorly ventilated high-altitude shelters with stoves/generators - especially dangerous as hypoxia worsens CO toxicity)
Alcohol hangover
CNS infection (meningitis)

Any focal neurologic sign, ataxia, or confusion should be treated as HACE or another serious cause until proven otherwise.

Murray & Nadel's, p. 3638

Key Diagnostic Principle

AMS is a clinical diagnosis. There are no confirmatory laboratory tests. The diagnosis rests entirely on history and symptom scoring in the right setting (recent ascent above ~2,400 m / 8,000 ft). A normal neurologic exam and normal mental status distinguish AMS from the more dangerous HACE.

Rabies pre post and re exposure prophylaxis regimens in india

Finding Sources

Searching the Web

India rabies pre-exposure post-exposure prophylaxis regimen NCDC APCRI 2024 guidelines

Reading Web Page

https://clinicalestablishments.mohfw.gov.in/sites/default/fi…

Reading File

Searching the Web

India rabies prophylaxis intradermal regimen Updated Essen Zagreb 2-site ID schedule APCRI wound categories

I now have comprehensive data from India's MoHFW National Guidelines, WHO recommendations, and major textbooks. Here is the complete answer:

Rabies Prophylaxis Regimens in India

India accounts for approximately 36% of global human rabies deaths (~20,000/year), with dogs responsible for over 95% of cases. The National Centre for Disease Control (NCDC), Ministry of Health & Family Welfare governs national guidelines. India exclusively uses Cell Culture Vaccines (CCVs) - nerve tissue vaccines (NTVs) are banned.

Step 1: Wound Category Classification (WHO/India)

The first step in ANY bite is to classify the exposure:

Category	Type of Contact	Action Required
I	Touching/feeding the animal; licks on intact skin	No prophylaxis needed - wash hands
II	Nibbling of uncovered skin; minor scratches/abrasions without bleeding; licks on broken skin	Wound wash + vaccination immediately
III	Single or multiple transdermal bites; scratches with bleeding; contamination of mucous membranes with saliva; licks on broken skin; contact with bats	Wound wash + vaccination + RIG immediately

Step 2: Wound Management (All Categories II & III)

This is the most important immediate step and must NEVER be skipped:

Wash wound thoroughly with soap and water for at least 15 minutes
Apply povidone-iodine (virucidal) or 70% alcohol to the wound
Do NOT suture the wound immediately (increases viral penetration)
Give tetanus prophylaxis if indicated
Give antibiotics if indicated for secondary infection

POST-EXPOSURE PROPHYLAXIS (PEP) - India's Preferred Regimen

Vaccines Available in India

Vaccine	Abbreviation	Volume
Purified Vero Cell Rabies Vaccine	PVRV	0.5 mL or 1 mL
Purified Chick Embryo Cell Vaccine	PCECV	1 mL
Human Diploid Cell Vaccine	HDCV	1 mL
Purified Duck Embryo Vaccine	PDEV	1 mL

Preferred Route: Intradermal (ID) - India's Standard Since 2004

India follows the 2-site intradermal (2-site ID) schedule - endorsed by WHO and NCDC - because it uses less vaccine per visit, is equally immunogenic, and significantly reduces cost.

Updated Thai Red Cross (TRC) / 2-Site ID Regimen (India's standard PEP)

Day	Sites	Dose per site	Notes
Day 0	2 sites (both deltoids)	0.1 mL each	+ RIG if Cat III
Day 3	2 sites (both deltoids)	0.1 mL each
Day 7	2 sites (both deltoids)	0.1 mL each
Day 28	2 sites (both deltoids)	0.1 mL each

Total visits: 4 (Days 0, 3, 7, 28)
Total vaccine used: equivalent to ~1 vial (cost-saving vs IM)
Site: deltoid region bilaterally; anterolateral thigh in infants

Alternative Route: Intramuscular (IM)

Essen Regimen (1-1-1-1-1) - Standard IM Schedule

Day	Dose	Route	Site
0	1 vial (0.5 or 1 mL)	IM	Deltoid
3	1 vial	IM	Deltoid
7	1 vial	IM	Deltoid
14	1 vial	IM	Deltoid
28	1 vial	IM	Deltoid

5 doses over 28 days
Never in the gluteal area (fat impairs absorption)
Infants: anterolateral thigh

Zagreb Regimen (2-1-1) - Faster IM Schedule

Day	Dose	Notes
0	2 doses (one in each deltoid)	Double dose on day 0
7	1 dose
21	1 dose

Only 3 visits over 21 days - useful for poor compliance situations

India note: The Essen 5-dose IM and the 2-site ID regimen are both government-approved. The ID route is preferred in government facilities due to cost.

Rabies Immunoglobulin (RIG) - Category III Only

RIG provides passive immediate immunity for the first 7-10 days until active vaccine-induced immunity develops. It is mandatory for Category III exposures only.

Types Available in India

Type	Abbreviation	Dose	Source
Human Rabies Immunoglobulin	HRIG	20 IU/kg body weight	Preferred; imported/expensive
Equine Rabies Immunoglobulin	ERIG	40 IU/kg body weight	Produced in India; cheaper; skin test recommended

How to Administer RIG (India guidelines, updated)

Infiltrate the ENTIRE dose directly into and around the wound
If anatomically not feasible (e.g., finger tip fully infiltrated), give remaining volume IM at a site distant from vaccine
Do NOT inject RIG in the same syringe or same site as the vaccine
RIG is given only ONCE on Day 0
If RIG was not given on Day 0, it can be administered up to Day 7 only - after Day 7 it is not beneficial (active immunity is already developing)
Previously vaccinated persons: RIG is NOT given

- National Guidelines on Rabies Prophylaxis, NCDC/MoHFW India - Tintinalli's Emergency Medicine, pp. 2207-2222

PRE-EXPOSURE PROPHYLAXIS (PrEP) - India

Who Should Get PrEP?

Laboratory staff handling rabies virus/infected material
Clinicians attending human rabies cases
Veterinarians and animal handlers/catchers
Wildlife wardens and quarantine officers
Travelers from rabies-free areas to India
Children (recommended by Indian Academy of Pediatrics - IAP, on voluntary basis)

PrEP Schedule

Day	IM Dose	ID Dose	Route
0	1 full vial	0.1 mL	IM or ID
7	1 full vial	0.1 mL	IM or ID
21 or 28	1 full vial	0.1 mL	IM or ID

3 doses total (Days 0, 7, and 21 or 28)
Provides immunological memory ("priming") - does NOT eliminate need for PEP after exposure, but eliminates need for RIG and reduces vaccine doses

Booster Doses After PrEP

Risk Category	Serology Monitoring	Booster Timing
Continuous risk (lab workers)	Every 6 months	If titer < acceptable level
Frequent risk (vets, cavers)	Every 2 years	If titer < acceptable level
Infrequent risk (travelers)	Not needed	Not required unless re-exposed

Goldman-Cecil Medicine; Tintinalli's, Table 158-2

RE-EXPOSURE PROPHYLAXIS (Previously Vaccinated)

If a person has previously received complete PrEP or PEP with a cell culture vaccine (CCV) or PDEV (documented), they have immunological memory. On re-exposure:

They Need ONLY:

Day	IM Dose	ID Dose
0	1 full vial IM	0.1 mL at 1 site
3	1 full vial IM	0.1 mL at 1 site

Just 2 doses (Days 0 and 3)
NO RIG - ever, regardless of wound category
This applies whether the prior vaccination was given IM or ID, and whether or not the person currently has detectable antibodies (anamnestic response is reliable)

If the previously vaccinated person received only a nerve tissue vaccine (NTV) - now banned in India but historically used - they should be treated as unvaccinated and receive full PEP with RIG.

- NCDC National Guidelines on Rabies Prophylaxis, India - Tintinalli's Emergency Medicine, p. 2226

Special Situations in India

Situation	Modification
Immunocompromised patients	Full 5-dose IM Essen regimen + RIG (even if Cat II); check serology after completion
Pregnancy	NOT a contraindication; give full PEP immediately - rabies is 100% fatal
Infants	Same doses; anterolateral thigh instead of deltoid
Head/face/neck bites	Cat III regardless - give RIG immediately, high-priority cases
If RIG unavailable	Do NOT delay vaccination; give vaccine immediately, administer RIG as soon as it becomes available (up to Day 7)

Quick Summary Table

	PrEP	PEP (Unvaccinated)	Re-exposure (Vaccinated)
Doses	3 (D0, D7, D21/28)	4-5 doses	2 (D0, D3)
ID schedule	0.1 mL × 1 site	0.1 mL × 2 sites (D0,3,7,28)	0.1 mL × 1 site
IM schedule	1 vial × 3 visits	Essen: 1 vial × 5 visits	1 vial × 2 visits
RIG	Not given	Cat III only (Day 0-7)	Never
Wound wash	N/A	Mandatory	Mandatory

This is a shared conversation. Sign in to Orris to start your own chat.